Repligen (NASDAQ:RGEN) Stock Price Up 5.9% – Here’s Why

Repligen Corporation (NASDAQ:RGEN)’s share price rose 5.9% during trading on Thursday . The company traded as high as $186.80 and last traded at $186.80. Approximately 645,660 shares were traded during trading, a decline of 36% from the average session volume of 1,015,015 shares. The stock had previously closed at $176.36.

Analyst Ratings Changes

A number of research analysts recently commented on RGEN shares. Royal Bank Of Canada started coverage on Repligen in a research note on Thursday, May 14th. They issued an “outperform” rating and a $160.00 price target for the company. Barclays boosted their target price on shares of Repligen from $145.00 to $160.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Wells Fargo & Company increased their price target on shares of Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a research report on Thursday, July 30th. HSBC decreased their price objective on shares of Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a research note on Wednesday, June 3rd. Finally, JPMorgan Chase & Co. raised their target price on Repligen from $165.00 to $175.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $166.43.

Repligen Price Performance

The business’s fifty day moving average price is $145.21 and its 200 day moving average price is $131.32. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.05 and a quick ratio of 7.64. The stock has a market cap of $10.39 billion, a P/E ratio of 252.26, a PEG ratio of 3.03 and a beta of 1.03.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.09. The company had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The firm’s revenue was up 11.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.26 EPS. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Sell-side analysts forecast that Repligen Corporation will post 2.06 EPS for the current fiscal year.

Insider Activity

In other news, CFO Jason K. Garland sold 733 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the transaction, the chief financial officer directly owned 19,359 shares in the company, valued at approximately $2,807,055. This represents a 3.65% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.60% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. M&T Bank Corp bought a new position in shares of Repligen during the fourth quarter valued at $29,819,000. Avidity Partners Management LP grew its stake in shares of Repligen by 54.7% in the first quarter. Avidity Partners Management LP now owns 77,800 shares of the biotechnology company’s stock worth $9,166,000 after purchasing an additional 27,500 shares during the last quarter. Swedbank AB acquired a new stake in Repligen in the fourth quarter valued at $4,146,000. Conestoga Capital Advisors LLC increased its holdings in Repligen by 10.6% in the fourth quarter. Conestoga Capital Advisors LLC now owns 1,057,975 shares of the biotechnology company’s stock valued at $173,360,000 after purchasing an additional 101,062 shares during the period. Finally, Jennison Associates LLC bought a new position in Repligen during the 4th quarter worth $20,253,000. Institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.